SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SAN DIEGO, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Sandra Matsumoto has been named Vice President of Global Regulatory Affairs effective immediately. In this role, Dr. Matsumoto will be responsible for global regulatory strategy and lifecycle management of the Evofem product portfolio. She will report to Evofem Senior Vice President of Regulatory Affairs and Quality Assurance, Mary Jarosz.
"Sandra has extensive experience in the biotech and pharmaceutical industry," said Jarosz. "She has implemented global strategies from development to commercialization across several therapeutic areas and is a great addition to a well-established regulatory team."
Prior to joining Evofem, Dr. Matsumoto was the Senior Director of Global Regulatory Affairs for Vital Therapeutics, Inc., where she led biologics license application preparation for the treatment of severe liver disease. Before joining Vital, she held positions with increasing levels of responsibility in the areas of regulatory affairs, clinical development, and discovery research with several companies including Shire Regenerative Medicine and Illumina.
Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master's of Science in Biology from California State University, Northridge and her Bachelor's of Science in Biology from UCLA. She also holds RAC certifications for the U.S. and E.U.
About Evofem
Evofem, Inc. is a late stage biotechnology company, headquartered in San Diego, CA, which focuses on the development and commercialization of women's reproductive health products, with a core focus on contraception.
Evofem, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates; Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
CONTACT: Media Inquiries
Ellen Thomas
+1.718.490.3248
[email protected]
